Senores Pharmaceuticals IPO Details
The key details of Senores Pharmaceuticals’s IPO are outlined below, covering all crucial aspects from price range to investment requirements and regulatory documents.
| IPO Size | ₹582.11 Cr |
| Price Range | ₹372 - ₹391 |
| Retail Quota | 10% |
| QIB Quota | 75% |
| NII Quota | 15% |
| Employee Discount | -- |
| Listing at | NSE and BSE |
| Minimum Quantity | 38 |
| Investment (cut-off price) | ₹14,858 |
| Pre IPO Promotor Holding | 71.10% |
| Post IPO Promotor Holding | Update soon |
| DHRP Draft | Click Here |
| RHP Draft | Click Here |
| Anchor Investors List | Click Here |
Senores Pharmaceuticals IPO Timelines
The IPO process for Senores Pharmaceuticals includes key dates for participants to know. The timeline allows for strategic planning and participation, helping investors stay informed and engaged throughout the entire process.
20/12/2024
Start Date24/12/2024
End Date27/12/2024
Refund Initiation27/12/2024
Credit of Shares to Demat Ac30/12/2024
Listing DateSenores Pharmaceuticals IPO Lot Size
The Senores Pharmaceuticals IPO has a fixed lot size of 38 shares, at an upper price band of ₹391 per share, requiring ₹14,858 per lot for retail investors. Retail investors can apply for a maximum of 494 shares worth ₹193,154. For Small HNI (S-HNI), the minimum application starts at 532 shares (₹208,012) up to 2,546 shares (₹995,486), while Big HNI (B-HNI) requires a minimum of 2,584 shares amounting to ₹1,010,344.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 38 | ₹14,858 |
| Retail Maximum | 13 | 494 | ₹1,93,154 |
| S-HNI Minimum | 14 | 532 | ₹2,08,012 |
| S-HNI Maximum | 67 | 2546 | ₹9,95,486 |
| B-HNI Minimum | 68 | 2584 | ₹10,10,344 |
Senores Pharmaceuticals IPO Subscription Status
The subscription status for Senores Pharmaceuticals IPO shows market demand across different investor categories, providing valuable insights into the offering’s performance. You can track real-time subscription data below.
| QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|
| 97.84x | 100.35x | 93.16x | -- | 97.86x |
IPO Performance on Listing Day
On the listing day (December 30, 2024), Senores Pharmaceuticals made a remarkable debut on the stock exchange. The stock opened at ₹600, delivering a strong premium of 53.5% over its issue price of ₹391. During the trading session, the stock witnessed active trading, touching a high of ₹609.65 before experiencing some profit booking that brought it to a low of ₹538.85. The shares concluded their first trading day at ₹562, locking in an impressive gain of 43.7% over the issue price, demonstrating significant investor confidence in this pharmaceutical company.
| Opening Price | Closing Price | Day High | Day Low |
|---|---|---|---|
| ₹600 | ₹562 | ₹609.65 | ₹538.85 |
Senores Pharmaceuticals IPO Company Financials
Senores Pharmaceuticals reports robust performance in FY2024 with Total Income of ₹217.34 crores, managing expenses at ₹192.40 crores, and achieving a strong PAT (Profit After Tax) of ₹32.71 crores, demonstrating significant growth potential ahead of its public offering.
| Year | Total Income | Total Expense | PAT |
|---|---|---|---|
| FY 2022 | ₹14.63 | ₹13.49 | ₹0.99 |
| FY 2023 | ₹39.02 | ₹26.58 | ₹8.43 |
| FY 2024 | ₹217.34 | ₹192.40 | ₹32.71 |
| FY 2025 (6 M) | ₹183.35 | ₹153.95 | ₹23.94 |
About Company
Senores Pharmaceuticals Limited, established in December 2017, is a rapidly growing pharmaceutical company focused on developing niche, complex, and specialty products for regulated markets like the US, Canada, and the UK, alongside emerging markets. With a diverse product portfolio covering key therapeutic areas such as antibiotics and antifungal treatments, the company has launched 55 products as of September 30, 2024. Senores operates three dedicated R&D facilities in India and the US, backed by a team of seasoned industry professionals driving innovation in affordable healthcare solutions.
The company’s manufacturing unit in Ahmedabad, Gujarat, produces critical care injectables, APIs, and other pharmaceutical formulations, adhering to global quality standards. It serves 43 countries across emerging markets and has established partnerships with distributors and hospitals in India. Guided by industry veterans, Senores Pharmaceuticals aims to make a significant impact on global healthcare with its commitment to excellence, sustainability, and innovation.
| Incorporation Date | Sector | Managing Director |
|---|---|---|
| 2017 | Pharmaceuticals | Swapnil Shah |
Know Before Investing
Senores Pharmaceuticals IPO Strengths
- Senores Pharmaceuticals has developed and commercialized a wide array of specialty and complex pharmaceutical products, enhancing its market appeal.
- The IPO proceeds will fund the establishment of a manufacturing facility for sterile injections, positioning the company for future growth.
- With three dedicated R&D facilities and plans to consolidate them, the company is well-equipped to innovate and expand its product offerings.
- The company operates in both regulated and emerging markets, reducing dependency on any single market and increasing growth opportunities.
Senores Pharmaceuticals IPO Risks
- The company has shown stagnant profit growth, raising concerns about long-term financial stability.
- Performance is heavily reliant on the pharmaceutical sector, which can be volatile and subject to changing market dynamics.
- The industry is competitive, with numerous established players that could impact market share and pricing strategies.
- A significant portion of IPO proceeds will be used for debt repayment, indicating existing financial leverage that could affect future stability.
Swot Analysis for Senores Pharmaceuticals IPO
Strengths
Specialty Product Focus, Strong Market Presence, Strategic Partnerships
Weaknesses
High Dependence on Regulatory Approvals, Limited Brand Recognition, Operational Losses
Opportunities
Growing Global Demand, Expansion Plans, Technological Advancements
Threats
Intense Competition, Economic Volatility, Regulatory Compliance Risks
Company Details
Senores Pharmaceuticals Limited
1101 to 1103, 11th floor,
South Tower, ONE 42 oppositeJayantilal Park,
Ambali Bopal Road, Ahmedabad,-380054
Phone: +91-79-29999857
Email: cs@senorespharma.com
Website: https://senorespharma.com/
IPO Registar Details
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: senorespharma.ipo@linkintime.co.in
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
FAQs
The key objectives of Senores Pharmaceuticals IPO are:
- Investment in Havix Group, Inc., to set up a sterile injection manufacturing facility in Atlanta.
- Repayment/prepayment of certain borrowings availed by the Company.
- Investment in Havix for repayment/prepayment of its borrowings.
- Funding working capital requirements of the Company.
- Investment in SPI and Ratnatris for their working capital needs.
- Funding acquisitions, strategic initiatives, and general corporate purposes.
Equirus Capital Private Limited, Ambit Private Limited and Nuvama Wealth Management Limited are the book-running lead managers for the Senores Pharmaceuticals IPO.